{"contentid": 487910, "importid": NaN, "name": "February 2021 pharmaceutical M&A round-up", "introduction": "There were not many acquisitions in the pharmaceutical industry in February, but three of them were in the billion dollar-plus category.", "content": "<p>There were not many acquisitions in the pharmaceutical industry in February, but three of them were in the billion dollar-plus category.</p>\n<p>The biggest of all was the largest of the year so far, with Jazz Pharmaceuticals (Nasdaq: JAZZ) paying $7.2 billion to buy cannabis company GW Pharmaceuticals.</p>\n<p>Our table below documents the month's acquisitions:</p>\n<table class=\"maTable maTableMonthly\" border=\"0\" cellspacing=\"0\" cellpadding=\"10\">\n<thead>\n<tr>\n<th><strong>Company</strong></th>\n<th><strong>Takeover&nbsp;candidate</strong></th>\n<th><strong>Value</strong></th>\n<th><strong>Why?</strong></th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td><a href=\"https://www.thepharmaletter.com/article/horizon-therapeutics-buys-viela-bio-for-3-05-billion\" rel=\"follow\">Horizon Therapeutics</a></td>\n<td><a href=\"https://www.thepharmaletter.com/article/horizon-therapeutics-buys-viela-bio-for-3-05-billion\" rel=\"follow\">Viel</a><a href=\"https://www.thepharmaletter.com/article/horizon-therapeutics-buys-viela-bio-for-3-05-billion\" rel=\"follow\">&nbsp;Bio</a></td>\n<td>$3.05 billion</td>\n<td>To expand Horizon's pipeline in order to accelerate its growth over the long term</td>\n</tr>\n<tr>\n<td><a href=\"https://www.thepharmaletter.com/article/biggest-pharma-m-a-deal-of-the-year-so-far-announced-by-jazz-pharma\" target=\"_blank\" rel=\"follow noopener\">Jazz Pharmaceuticals </a></td>\n<td><a href=\"https://www.thepharmaletter.com/article/biggest-pharma-m-a-deal-of-the-year-so-far-announced-by-jazz-pharma\" target=\"_blank\" rel=\"follow noopener\">GW Pharmaceuticals</a></td>\n<td>$7.2 billion</td>\n<td>To add an industry-leading cannabinoid platform, innovative pipeline and products, to strengthen and broaden Jazz's neuroscience portfolio</td>\n</tr>\n<tr>\n<td><a href=\"https://www.thepharmaletter.com/article/novo-holdings-to-acquire-altasciences\" rel=\"follow\">Novo Holdings</a></td>\n<td><a href=\"https://www.thepharmaletter.com/article/novo-holdings-to-acquire-altasciences\" rel=\"follow\">Altasciences</a></td>\n<td>Undisclosed</td>\n<td>To acquire a company that is well-positioned to capture share in the fast-growing market for drug development services</td>\n</tr>\n<tr>\n<td><a href=\"https://www.thepharmaletter.com/article/beam-therapeutics-down-as-it-acquires-guidetx\" rel=\"follow\">Beam Therapeutics</a></td>\n<td><a href=\"https://www.thepharmaletter.com/article/beam-therapeutics-down-as-it-acquires-guidetx\" rel=\"follow\">Guide Therapeutics</a></td>\n<td>$120 million plus $320 million in milestones</td>\n<td>To&nbsp;further expand the potential reach of Beam&rsquo;s genetic medicines into new target tissues and diseases</td>\n</tr>\n<tr>\n<td><a href=\"https://www.thepharmaletter.com/article/merck-getting-on-treg-train-with-1-85b-acquisition\" rel=\"follow\">Merck &amp; Co</a></td>\n<td><a href=\"https://www.thepharmaletter.com/article/merck-getting-on-treg-train-with-1-85b-acquisition\" rel=\"follow\">Pandion Therapeutics</a></td>\n<td>$1.85 billion</td>\n<td>To&nbsp;build upon Merck&rsquo;s strategy to identify and secure candidates with differentiated and potentially foundational characteristics</td>\n</tr>\n</tbody>\n</table>", "date": "2021-03-01 17:53:00", "meta_title": NaN, "meta_keywords": "billion, February, pharmaceutical, Pharmaceuticals, Therapeutics, acquisitions, company, Jazz, round-up, dollar-plus, industry, category, Takeovercandidate", "meta_description": "There were not many acquisitions in the pharmaceutical industry in February, but three of them were in the billion dollar-plus category.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-01 17:01:25", "updated": "2021-03-01 18:24:45", "access": NaN, "url": "https://www.thepharmaletter.com/article/february-2021-pharmaceutical-m-a-round-up", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "merger-large.jpg", "image2id": "merger-small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": NaN, "topic_tag": "Companies, mergers and acquisitions", "geography_tag": NaN, "company_tag": "Horizon Therapeutics, Jazz Pharmaceuticals, Merck & Co", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-01 17:53:00"}